Phase II Study Assessing the Efficacy and Toxicity of Olverembatinib Monotherapy in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase

This study is testing a drug called olverembatinib as a single treatment for adults newly diagnosed with chronic myeloid leukemia (CML) — a type of blood cancer caused by a specific genetic abnormality called the Philadelphia chromosome or BCR-ABL1 fusion. Olverembatinib is a targeted therapy designed to block the abnormal protein that drives CML. Researchers want to see how well it works as a first-line treatment. **You may be eligible if...** - You are 18 or older - You have been newly diagnosed with Philadelphia chromosome-positive CML in the chronic phase (an early, less aggressive stage) - You may have had very short prior treatment (hydroxyurea, a small dose of cytarabine, or a TKI for 30 days or fewer) - Your organ function (liver, kidney) is adequate **You may NOT be eligible if...** - Your CML has progressed to an accelerated or blast phase - You have significant organ dysfunction - You are unable to take oral medications Talk to your doctor to see if this trial is right for you.